Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Optimising regorafenib dosing in mCRC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.08.19
Views: 457
Rating:

Dr Axel Grothey and Dr Tanios Bekaii-Saab

Regorafenib has become a standard later stage treatment of metastatic colorectal carcinoma (mCRC) worldwide, though particular side effects such as fatigue and diarrhoea complicate its use in practice. Until now, consensus was split on how to use regorafenib for effective treatment - should the full dose be initiated and reduced until tolerated, or should a lower initial dose be used with a view to titrate up?

The REDOS trial evaluated the safety and activity of two regorafenib dosing schedules in patients with refractory mCRC. An escalation strategy was implemented to optimise the dose of regorafenib and to improve the tolerability of this drug to patients while maintaining survival benefits.

Join lead investigator Dr Tanois Bekaii-Saab and Dr Axel Grothey for a critical analysis of the trial, and a discussion of future directions in this therapy area.

If you are from Spain, Italy, France or the USA and want to listen to advice from experts from your country, please visit Oncology knowledge into practice.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. All educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

 

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation